



OPEN ACCESS

EDITED AND REVIEWED BY
Fan Yang,
Henan University of Science and
Technology, China

*CORRESPONDENCE
Changbaig Hyun
✉ changbaig@gmail.com

RECEIVED 18 August 2025
ACCEPTED 26 August 2025
PUBLISHED 11 September 2025

CITATION
Park J, Lee J, Lee S-J and Hyun C (2025)
Correction: Clinical evaluation of a novel
fixed-dose combination tablet (Sentorpil®
ForteGold) versus compounded powdered
medications in dogs with myxomatous mitral
valve disease: a randomized, double-blind
study. *Front. Vet. Sci.* 12:1687939.
doi: 10.3389/fvets.2025.1687939

COPYRIGHT
© 2025 Park, Lee, Lee and Hyun. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Correction: Clinical evaluation of a novel fixed-dose combination tablet (Sentorpil® ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study

Jiyoung Park, Jiyoung Lee, Sang-Joon Lee and Changbaig Hyun*

Hyun Changbaig Animal Heart Institute, VIP Animal Medical Center, Seoul, Republic of Korea

KEYWORDS

myxomatous mitral valve disease, fixed-dose combination tablet, canine cardiology, ForteGold, randomized clinical trial

A Correction on

Clinical evaluation of a novel fixed-dose combination tablet (Sentorpil® ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study

by Park, J., Lee, J., Lee, S. -J., and Hyun, C. (2025). *Front. Vet. Sci.* 12:1622383.
doi: 10.3389/fvets.2025.1622383

The occurrence of “Sentorphil” has been updated to the correct spelling of “Sentorpil®” throughout the article.

The title of this article was erroneously given as: Clinical Evaluation of a Novel Fixed-Dose Combination Tablet (Sentorphil® ForteGold) Versus Compounded Powdered Medications in Dogs with Myxomatous Mitral Valve Disease: A Randomized, Double-Blind Study.

The correct title of the article is: Clinical evaluation of a novel fixed-dose combination tablet (Sentorpil® ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study.

In **Abstract, Methods**, page 1.

The incorrect sentence previously stated:

“In a randomized, double-blind clinical trial, 60 client-owned dogs diagnosed with ACVIM stage C MMVD were assigned to receive either a novel fixed-dose combination tablet (Sentorphil® ForteGold) or a compounded powdered mixture of torsemide, pimobendan, enalapril, and spironolactone.”

The corrected sentence appears below:

“In a randomized, double-blind clinical trial, 60 client-owned dogs diagnosed with ACVIM stage C MMVD were assigned to receive either a novel fixed-dose combination

tablet (Sentorphil[®] ForteGold) or a compounded powdered mixture of torsemide, pimobendan, enalapril, and spironolactone.”

In **Abstract**, *Discussion*, page 1.

The incorrect sentence previously stated:

“The fixed-dose combination tablet (Sentorphil[®] ForteGold) offers a clinically effective and safer alternative to compounded powdered medications for managing MMVD in dogs.”

The corrected sentence appears below:

“The fixed-dose combination tablet (Sentorphil[®] ForteGold) offers a clinically effective and safer alternative to compounded powdered medications for managing MMVD in dogs.”

In *Citation*, page 1:

The incorrect Citation previously stated:

“Park J, Lee J, Lee S-J and Hyun C (2025) Clinical evaluation of a novel fixed-dose combination tablet (Sentorphil[®] ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study. *Front. Vet. Sci.* 12:1622383. doi: 10.3389/fvets.2025.1622383.”

The corrected Citation appears below:

“Park J, Lee J, Lee S-J and Hyun C (2025) Clinical evaluation of a novel fixed-dose combination tablet (Sentorphil[®] ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study. *Front. Vet. Sci.* 12:1622383. doi: 10.3389/fvets.2025.1622383”

In **Introduction**, paragraph 4, page 2:

The incorrect sentence previously stated:

“This study aimed to evaluate the clinical efficacy, safety profile, and practical advantages of (Sentorphil[®] ForteGold), a newly developed fixed-dose combination tablet, compared with traditional compounded powder formulations.”

The corrected sentence appears below:

“This study aimed to evaluate the clinical efficacy, safety profile, and practical advantages of (Sentorphil[®] ForteGold), a

newly developed fixed-dose combination tablet, compared with traditional compounded powder formulations.”

In **Materials and methods**, paragraph 1, page 2:

The incorrect sentence previously stated:

“Group 1 received (Sentorphil[®] ForteGold) (Careside, Korea), a tablet containing torsemide (0.2 mg), pimobendan (0.6 mg), enalapril maleate (1.0 mg), and spironolactone (2.0 mg), dosed at one tablet per 2 kg of body weight, administered twice daily.”

The corrected sentence appears below:

“Group 1 received (Sentorphil[®] ForteGold) (Careside, Korea), a tablet containing torsemide (0.2 mg), pimobendan (0.6 mg), enalapril maleate (1.0 mg), and spironolactone (2.0 mg), dosed at one tablet per 2 kg of body weight, administered twice daily.”

In **Discussion**, paragraph 10, page 10:

The incorrect sentence previously stated:

“However, since Sentorphil[®] ForteGold is formulated to allow dose adjustment through tablet splitting, it enables more precise and individualized dosing, thereby helping to mitigate these risks.”

The corrected sentence appears below:

“However, since Sentorphil[®] ForteGold is formulated to allow dose adjustment through tablet splitting, it enables more precise and individualized dosing, thereby helping to mitigate these risks.”

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.